Table 2. Administration status of concomitant antihypertensive agentsa.
|
Age at baseline (years) |
||||
|---|---|---|---|---|
| <65 | 65–74 |
⩾75 |
||
| (n=9817) | (n=6792) | (n=4732) | ⩾80 subgroup (n=2095) | |
| At start of olmesartan treatment | ||||
| Receiving concomitant antihypertensive agents ⩾1 | 3156 (32.1) | 2825 (41.6) | 2299 (48.6) | 1054 (50.3) |
| Calcium channel blockers | 2745 (28.0) | 2484 (36.6) | 2016 (42.6) | 916 (43.7) |
| β-Blockers | 464 (4.7) | 450 (6.6) | 362 (7.7) | 169 (8.1) |
| Diuretics | 327 (3.3) | 311 (4.6) | 323 (6.8) | 162 (7.7) |
| α-Blockers | 139 (1.4) | 142 (2.1) | 155 (3.3) | 63 (3.0) |
| Angiotensin-converting enzyme inhibitors | 105 (1.1) | 107 (1.6) | 97 (2.0) | 42 (2.0) |
| Angiotensin II receptor blockers | 54 (0.6) | 53 (0.8) | 53 (1.1) | 23 (1.1) |
| Other | 29 (0.3) | 19 (0.3) | 26 (0.5) | 13 (0.6) |
| No. of antihypertensive drugs (including olmesartan) | 1.4±0.7 | 1.5±0.7 | 1.7±0.8 | 1.7±0.8 |
| At 16 weeks | ||||
| Receiving concomitant antihypertensive agents ⩾1 | 3934 (40.1) | 3143 (46.3) | 2511 (53.1) | 1132 (54.0) |
| Calcium channel blockers | 3408 (34.7) | 2773 (40.8) | 2208 (46.7) | 990 (47.3) |
| β-Blockers | 529 (5.4) | 474 (7.0) | 383 (8.1) | 180 (8.6) |
| Diuretics | 551 (5.6) | 451 (6.6) | 401 (8.5) | 193 (9.2) |
| α-Blockers | 171 (1.7) | 164 (2.4) | 174 (3.7) | 70 (3.3) |
| Angiotensin-converting enzyme inhibitors | 105 (1.1) | 105 (1.5) | 99 (2.1) | 42 (2.0) |
| Angiotensin II receptor blockers | 58 (0.6) | 53 (0.8) | 50 (1.1) | 23 (1.1) |
| Other | 45 (0.5) | 32 (0.5) | 35 (0.7) | 17 (0.8) |
| No. of antihypertensive drugs (including olmesartan) | 1.5±0.7 | 1.6±0.8 | 1.7±0.9 | 1.7±0.9 |
a
n (%).